Inactivation of VHL leads to activation of VEGF and PDGF and targets the downstream glutamine transporter SLC1A5, promoting metabolic reprogramming of VHL-deficient RCC and selectively reducing the growth of VHL-deficient RCC [227]. This evidence concerns the gene SLC1A5 and renal cell carcinoma.